Swiss NASH Foundation sponsorship

Published on 11/03/2022

We are pleased to sponsor the Swiss NASH Foundation launched in 2019 by Pr Jean-François Dufour. Its mission is to raise awareness and increase the knowledge about NASH and fatty liver in general. Through funding innovative research projects on NASH diagnostics, treatment and patient management, the foundation is joining the fight against this epidemic disease.

https://swissnashfoundation.org/

Read next in 'Latest news'

• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH
• New publication : An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters
• ENYO Pharma in the Top 50 of the EIC ScalingUp List
• Selection in the Best of the Liver Meeting 2021